| Filed On | Filing |
|---|---|
| 15 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 15, 2026, Indivior Pharmaceuticals, Inc. (“Indivior”) held a special meeting of its stockholders (the “Indivior Special Meeting”). At the close of business on September 4, 2026, the record date for the Indivior Special Meeting... |
| 06 Oct 2026 | 425 |
| 06 Oct 2026 |
8-K: Other Events
As previously reported, on August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (the “Indivior”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware cor... |
| 30 Sep 2026 | SCHEDULE 13G |
| 17 Sep 2026 | 425 |
| 17 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction |
| 15 Sep 2026 |
8-K: Termination of a Material Definitive Agreement
PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. REDACTED MATERI... |
| 11 Sep 2026 | EFFECT |
| 11 Sep 2026 | 424B3 |
| 09 Sep 2026 | S-4/A |
| 28 Aug 2026 | S-4 |
| 27 Aug 2026 |
Form 4: Anderson Woodrow D, Chief Accounting Officer
Bought 1,500 shares ($53.5K) |
| 13 Aug 2026 | SCHEDULE 13D/A |
| 05 Aug 2026 |
Form 4: Anderson Woodrow D, Chief Accounting Officer
Bought 1,500 shares ($54.4K) |
| 04 Aug 2026 | 425 |
| 03 Aug 2026 | 425 |
| 03 Aug 2026 | 10-Q |
| 03 Aug 2026 | 425 |
| 03 Aug 2026 | 8-K: Regulation FD Disclosure |
| 03 Aug 2026 | 425 |
Loading...